(Q74187188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

review article

1 reference

title

Development of anti-TNF therapy for rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

Marc Feldmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 May 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

364-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

The nucleotide sequence of human fibroblast interferon cDNA

9 November 2019

cites work

1 reference

Synthesis in E. coli of a polypeptide with human leukocyte interferon activity

31 March 2020

1 reference

Expression of human immune interferon cDNA in E. coli and monkey cells.

31 March 2020

1 reference

Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity

31 March 2020

1 reference

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

31 March 2020

1 reference

Filgrastim (r-metHuG-CSF) in the 21st century: SD/01.

31 March 2020

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

31 March 2020

1 reference

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

31 March 2020

1 reference

31 March 2020

1 reference

Rheumatoid arthritis. Pathophysiology and implications for therapy

31 March 2020

1 reference

Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis

31 March 2020

1 reference

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

31 March 2020

1 reference

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

31 March 2020

1 reference

Cytokine production in culture by cells isolated from the synovial membrane

31 March 2020

1 reference

Role of cytokines in rheumatoid arthritis

31 March 2020

1 reference

Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever

31 March 2020

1 reference

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

31 March 2020

1 reference

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

31 March 2020

1 reference

Type II collagen autoimmunity in animals and provocations leading to arthritis

31 March 2020

1 reference

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

31 March 2020

1 reference

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

31 March 2020

1 reference

Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect

31 March 2020

1 reference

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

31 March 2020

1 reference

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

31 March 2020

1 reference

Designing CD4 immunoadhesins for AIDS therapy

31 March 2020

1 reference

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

31 March 2020

1 reference

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

31 March 2020

1 reference

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

31 March 2020

1 reference

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

Cellular sites of immunologic unresponsiveness

31 March 2020

1 reference

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

31 March 2020

1 reference

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells

31 March 2020

1 reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

31 March 2020

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

31 March 2020

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

31 March 2020

1 reference

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

31 March 2020

1 reference

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

31 March 2020

1 reference

Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis

31 March 2020

1 reference

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

31 March 2020

1 reference

Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis

31 March 2020

1 reference

Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade

31 March 2020

1 reference

Manipulation of T-cell responses with monoclonal antibodies

31 March 2020

1 reference

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

31 March 2020

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

31 March 2020

1 reference

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

31 March 2020

1 reference

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2020

1 reference

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

31 March 2020

1 reference

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

31 March 2020

1 reference

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

31 March 2020

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

Progress in the treatment of rheumatoid arthritis

31 March 2020

1 reference

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

31 March 2020

1 reference

Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis

31 March 2020

1 reference

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

31 March 2020

1 reference

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

31 March 2020

1 reference

The mechanism of immunological paralysis.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRI802

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12033742%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference